Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma

Haematologica

Volumn 100, Issue 6, 2015, Pages 794-800

  Frankel, Arthur E ^a   Woo, Jung H ^b   Ahn, Chul ^a   Foss, Francine M ^c   Duvic, Madeleine ^d   Neville, Paul H ^e   Neville, David M ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Angimmune LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; GANCICLOVIR; IMMUNOTOXIN; PHOSPHATE; RESIMMUNE; RITUXIMAB; UNCLASSIFIED DRUG; CD3 ANTIGEN; CD3E PROTEIN, HUMAN; DIPHTHERIA TOXIN; IMMUNOGLOBULIN FRAGMENT; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CARDIOMEGALY; CARDIOVASCULAR DISEASE; CHILL; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CUTANEOUS T CELL LYMPHOMA; DEATH; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; EDEMA; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; IMMUNE RESPONSE; KIDNEY FAILURE; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LIVER FAILURE; MALE; MODIFIED SKIN WEIGHTED ASSESSMENT TOOL; MULTICENTER STUDY; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL; PROLYMPHOCYTIC LEUKEMIA; TREATMENT OUTCOME; VASCULAR LEAK SYNDROME; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA, T-CELL, CUTANEOUS; MIDDLE AGED; PROCEDURES; REMISSION; VASCULAR DISEASE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; COHORT STUDIES; DIPHTHERIA TOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; INFUSIONS, INTRAVENOUS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REMISSION INDUCTION; VASCULAR DISEASES; YOUNG ADULT;

EID: 84930508911     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.123711     Document Type: Article

References (44)

1. Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol. 2011;155(2):150-166
2. Imam MH, Shenoy PJ, Flowers CR, Phillips A, Lechowicz MJ. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma. 2013;54(4):752-759
3. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) Part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70(2):205.e1-205.e16
4. Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051-5060
5. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) Part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70(2):223.e1-223.e17
6. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibodydrug conjugates. Cancer Res. 2011;71(20): 6300-6309
7. Thompson J, Stavrou S, Weetall M, et al. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng. 2001;14(12):1035-1041
8. Arnett KL, Harrison SC, Wiley DC. Crystal structure of a human CD3-ε/δ dimer in complex with a UCHT1 single-chain antibody fragment. Proc Natl Acad Sci USA. 2004;101 (46):16268-16273
9. Izban KF, His ED, Alkan S. Immunohistochemical analysis of mycosis fungoides on paraffin-embedded tissue sections. Mod Pathol. 1998;11(10):978-982
10. Hexham JM, Dudas D, Hugo R, et al. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins. Mol Immunol. 2001;38(5):397-408
11. Woo JH, Liu JS, Kang SH, et al. GMP production and characterization of the bivalent anti-human T cell immunotoxin, AdmDT390-bisFv(UCHT1) for phase I/II clinical trials. Protein Expr Purif. 2008;58(1):1-11
12. Woo JH, Bour SH, Dang T, et al. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1). Cancer Immunol Immunother. 2008;57(8):1225-1239
13. Scarisbrick JJ, Kim YH, Whittaker SJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now? Br J Dermatol. 2014;170(6):1226-1236
14. Neville DM, Srinivasachar K, Stone R, Scharff J. Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants. J Biol Chem 1989;264(25):14653-14661
15. Thompson J, Hu H, Scharff J, Neville DM. An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. J Biol Chem 1995;270(47): 28037-28041
16. Woo JH, Lee Y, Neville DM, Frankel AE. Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T cell lymphoma trials. Methods Mol Biol. 2010;651:157-175
17. Wilcox RA. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89 (8):837-851
18. Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) Part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70(2): 223.e1-223.e17
19. Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk. 2013;13(4):377-384
20. Schmitz N, Wu HS, Glass B. Allogeneic transplantation in T-cell lymphomas. Semin Hematol. 2014;51(1):67-72
21. Jokinen CH, Fromm JR, Argenyi ZB, et al. Flow cytometric evaluation of skin biopsies for mycosis fungoides. Am J Dermatopathol. 2011;33(5):483-491
22. Gniadecki R. Lack of membrane expression of interleukin-2 receptor chain (CD25) in mycosis fungoides: application of laser scanning cytometry for phenotyping of skin infiltrating lymphocytes. J Invest Dermatol. 2000;114(3):594-595
23. Re GG, Waters C, Poisson L, et al. Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res. 1996;56(11):2590-2595
24. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144
25. Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385-392
26. Thorburn J, Horita H, Redzic J, et al. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 2009;16(1):175-183
27. Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2002;2:1-12
28. Klebanoff CA, Khong HT, Antony PA, et al. Sinks, supressors and antigen presenters: how lymphodepletion enhances T cellmediated tumor immunotherapy. Trends Immunol. 2005;26(2):111-117
29. Johnson VE, Vonderheid EC, Hess AD, et al. Genetic markers associated with progression in early mycosis fungoides. J Eur Acad Dermatol Venereol. 2014;28(11):1431-1435
30. Vaque JP, Gomez-Lopez G, Monsalvez V, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood. 2014;123(13):2034-2043
31. Ferrara G, Pancione M, Votino C, et al. A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides. Br J Dermatol. 2014;170(6):1266-1275
32. Litvinov IV, Jones DA, Sasseville D, Kupper TS. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clin Cancer Res. 2010;16(7):2106-2114
33. Frankel AE, Zuckero SL, Mankin AA, et al. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Curr Drug Targets. 2009;10(2):104-109
34. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant antimesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelinexpressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13 (17):5144-5149
35. Olsen E, Duvic M, Frankel AE, et al. Pivotal phase III trial of two dose levels of denileukin diftitoxfor the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19(2):376-388
36. Lindstrom AL, Erlandsen SL, Kersey JH, Pennell CA. An in vitro model for toxinmediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers. Blood. 1997;90(6):2323-2334
37. Baluna R, Vitetta ES. An in vivo model to study immunotoxin-induced vascular leak in human tissue. J Immunother. 1999;22(1):41-47
38. Frankel AE, Liu JS, Rizzieri D, Hogge D. Phase 1 clinical study of diphtheria toxininterleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49(3):543-553
39. Frankel AE, Powell BL, Hall PD, et al. Phase 1 trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002;8(5):1004-1013
40. Telang S, Rasku MA, Clem AL, et al. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patiens with unresectable stage IV melanoma. BMC Cancer. 2011;11:515
41. Cina RA, Wikiel KJ, Lee PW, et al. Stable multilineage chimerism without graft versus host disease following nonmyeloablative haploidentical hematopoietic cell transplantation. Transplantation. 2006;81(12):1677-1685
42. Contreras JL, Jenkins S, Eckhoff DE, et al. Stable alpha-and beta-islet cell function after tolerance induction to pancreatic islet allografts in diabetic primates. Am J Transplant. 2003;3(2):128-138
43. Hettiaratchy S, Melendy E, Randolph MA, et al. Tolerance to composite tissue allografts across a major histocompatibility barrier in miniature swine. Transplantation. 2004;77(4):514-521
44. Hogge DE, Feuring-Buske M, Gerhard B, et al. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leuk Res. 2004;28(11): 1221-1226.